A future frataxin replacement therapy for the brain


Radio 5 (RNE) interviews Ernest Giralt, head of the Design, Synthesis and Structure of Peptides and Proteins Lab at IRB Barcelona, and Macarena Sánchez, research associate in the same Lab, about IRB Barcelona’s research to tackle Friedreich’s ataxia. In the interview, Giralt explains that Friedreich’s ataxia is a hereditary degenerative disease that normally appears between the ages of 5 and 25, for which there is currently no cure.

IRB Barcelona’s project, supported by the patient and family association, the Babel Family, and the Asociación Granadina de la ataxia de Friedreich, aims to complete a step necessary to move towards a future frataxin replacement therapy for the brain. Reduced levels of this protein cause the most damage in patients with Friedreich’s ataxia.

Listen to the interview on  Radio 5